ME‐401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3‐KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B‐CELL LYMPHOID MALIGNANCIES. (June 2017) - Ghalie, R.G.